Fusion Biopsy Market: as GLOBOCAN 2022's 1,467,854 global prostate cancer cases and the Prostate Cancer Foundation's April 2024 projection of doubling to 2.9 million cases by 2040 establish the irreducible epidemiological demand base for superior biopsy accuracy, Philips UroNav's dominant US academic centre installed base and KOELIS Trinity's 3D elastic registration technology are driving a paradigm shift from conventional systematic TRUS-guided biopsy toward targeted MRI-US fusion procedures, so EAU 2024 guideline mandating pre-biopsy MRI plus targeted biopsy converts European hospital procurement decisions from capital equipment choices into clinical compliance requirements, and the September 2024 KOELIS-DeepHealth AI integration removes the specialist prostate MRI radiologist dependency that has been the primary adoption barrier in community urology and secondary hospitals.

The global fusion biopsy market size was USD 794.2 Million in 2025 and is expected to register a revenue CAGR of 8.6% during the forecast period. Market revenue growth is driven by factors such as GLOBOCAN 2022's documentation of 1,467,854 global prostate cancer cases establishing the epidemiological demand base for superior biopsy accuracy, EAU 2024 guideline mandating pre-biopsy MRI plus targeted biopsy converting clinical preference into institutional compliance requirements at European hospital urology programmes, and AI integration through the KOELIS-DeepHealth September 2024 collaboration removing the specialist prostate MRI radiologist dependency that has limited fusion biopsy adoption at community urology practices and secondary hospitals. The first driving factor is the accelerating global prostate cancer incidence trajectory. GLOBOCAN 2022 documented 1,467,854 new prostate cancer cases globally making prostate cancer the fourth most commonly diagnosed cancer worldwide at 7.3% of all new cancer cases, and the Prostate Cancer Foundation reported in April 2024 that prostate cancer cases are projected to double from 1.4 million in 2020 to 2.9 million annually by 2040 with annual deaths rising by 85% to nearly 700,000, establishing the structural epidemiological growth trajectory that drives fusion biopsy platform adoption. The second driving factor is the clinical evidence base demonstrating fusion biopsy superiority over systematic TRUS-guided biopsy. The Siddiqui et al. JAMA 2015 study demonstrated that MRI-US fusion-guided biopsy detected 30% more high-risk prostate cancers than standard ultrasound-guided biopsy and 17% fewer low-risk cancers, with the PRECISION trial in the New England Journal of Medicine 2018 and the PROMIS study in The Lancet 2017 reinforcing superiority, driving EAU 2024 and NICE guideline mandating pre-biopsy MRI plus targeted biopsy. The third driving factor is EAU 2024 guideline compliance converting European hospital procurement from discretionary to mandatory. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the KOELIS-DeepHealth AI integration announced September 2024, which automates prostate gland segmentation, PI-RADS lesion identification, and fusion target generation from pre-procedural MRI data without requiring a dedicated prostate MRI reporting radiologist at the point of biopsy, removing the primary adoption barrier that has limited fusion biopsy deployment to academic and specialist urology centres with dedicated prostate MRI reporting radiologists and potentially doubling the addressable market by 2030 by enabling community urology practices and secondary hospitals to adopt fusion biopsy without dedicated prostate MRI radiology infrastructure. Once an AI-assisted prostate MRI interpretation tool can generate a clinically validated PI-RADS-equivalent report that transfers directly to the fusion biopsy system, the community urology practice that previously could not adopt fusion biopsy without sending MRI scans to a radiology reading centre can now perform fusion-guided biopsy on its own schedule and within its own workflow, so the per-platform deployment revenue opportunity expands proportionally with the number of urology centres that the AI-enabled workflow puts within reach. For instance, in October 2024, Boston Scientific Corporation launched the AVVIGO Plus multi-modality fusion platform for urological applications including prostate fusion biopsy, expanding competitive platform availability from a major medical device manufacturer with established urology market distribution infrastructure, which is one of several confirmatory signals that large urology device companies are making strategic commitments to the fusion biopsy category. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the accelerating global prostate cancer incidence trajectory documented by GLOBOCAN 2022 and the Prostate Cancer Foundation, which establishes a demand base for superior biopsy accuracy that grows independently of any individual platform's commercial execution and that structural demographic aging ensures will compound through the forecast period regardless of screening policy variations or macroeconomic conditions. Epidemiological demand for superior biopsy accuracy works as a structural growth driver because the clinical consequence of missed high-risk prostate cancer at initial biopsy is delayed treatment access and increased cancer-specific mortality, creating a clinical imperative for precision targeting that drives guideline development, institutional investment, and physician adoption independent of device company commercial efforts. GLOBOCAN 2022 documented 1,467,854 new prostate cancer cases globally, making prostate cancer the fourth most commonly diagnosed cancer worldwide at 7.3% of all new cancer cases and the most commonly diagnosed cancer in men in 112 countries per the World Cancer Research Fund citing the GLOBOCAN 2022 database. The Siddiqui et al. JAMA 2015 study demonstrated that MRI-US fusion-guided biopsy detected 30% more high-risk prostate cancers and 17% fewer low-risk cancers compared to standard systematic biopsy, and this clinical superiority was reinforced by the PRECISION trial published in the New England Journal of Medicine in 2018 and the PROMIS study published in The Lancet in 2017. The effect on the market is a structural, epidemiologically-grounded demand base that grows with prostate cancer incidence and accumulates clinical evidence mass that makes reverting to conventional systematic TRUS-guided biopsy in guideline-adherent institutions progressively more difficult. These are some of the key factors driving revenue growth of the market.

The second driver is the EAU 2024 guideline mandate for pre-biopsy multiparametric MRI plus targeted biopsy as the preferred diagnostic pathway for biopsy-naive men with elevated PSA, which converts European hospital urology programme fusion biopsy procurement from a discretionary capital equipment improvement into a clinical compliance requirement that triggers institutional procurement even at hospitals without pre-existing capital equipment expansion plans. Guideline mandate conversion works as a structural demand driver because European university hospital ENT and urology programme clinical directors operate within accreditation frameworks that require alignment with EAU guideline standards, and a mandatory pre-biopsy MRI plus targeted biopsy recommendation creates a procurement obligation for MRI-US fusion biopsy capability that does not require an individual hospital's own cost-benefit analysis to justify. When the EAU published its 2021 guidelines recommending multiparametric MRI before prostate biopsy as the preferred pathway for biopsy-naive men, European university hospitals essentially had no choice but to implement it within their tenure evaluation and quality assessment frameworks, and the 2024 update reinforcing this standard with additional clinical evidence strengthened the compliance obligation. KOELIS has been the primary European beneficiary in France and francophone Europe because of its home market advantage and the Trinity system's clinical differentiation through 3D elastic registration, while Philips UroNav remains dominant at the largest German university urology centres because of long-standing Philips imaging infrastructure relationships. The effect on the market is a wave of platform procurement decisions across European secondary hospitals that have not yet upgraded their biopsy workflow to MRI-targeted approach, creating a 2025 to 2028 compliance-driven adoption wave above the baseline organic growth rate. These are some of the key factors driving revenue growth of the market.

"The KOELIS-DeepHealth AI integration announced September 2024 is commercially significant in Europe for a reason that goes beyond operational efficiency. If AI can provide a clinically validated PI-RADS-equivalent MRI interpretation that transfers directly to the fusion biopsy system, it opens the fusion biopsy market to smaller European hospitals and urology clinics in Southern and Eastern Europe that currently have prostate cancer patients needing biopsy but no local prostate MRI reporting radiologist. That is the commercial expansion case that makes this a potentially market-expanding rather than just operationally improving development."

Clarivant Analyst Intelligence, Q1 2026

The third driver is the structural shift from transrectal to transperineal fusion biopsy approach driven by the infection-control superiority of the transperineal route that eliminates the sepsis risk from transrectal needle passage through rectal mucosa, which creates incremental total biopsy volume as institutions that previously avoided post-biopsy sepsis risk by limiting biopsy frequency can now perform biopsies more readily with the lower-risk transperineal approach. Transperineal adoption works as a compounding volume driver because the approximately 1 to 3 percent post-transrectal biopsy sepsis rate creates meaningful clinical and medico-legal risk that some urology programmes manage by restricting biopsy to only the highest-risk PSA-elevated patients, and the transperineal route's elimination of this sepsis risk allows those programmes to follow EAU guideline-recommended biopsy thresholds without the sepsis rate concern that previously justified more conservative biopsy frequency. In March 2025, KOELIS announced the US commercial launch of the Trinity 3D MRI/ultrasound fusion biopsy system enabling both transrectal and transperineal fusion biopsy procedures in outpatient urology settings, with the system's proprietary 3D elastic registration technology compensating for prostate gland deformation during needle insertion to improve targeting accuracy compared to rigid registration platforms. BK Medical released an upgraded transperineal biopsy navigation system with AI-guided targeting tools in January 2025, confirming the growing commercial focus on transperineal fusion biopsy across multiple platform vendors simultaneously. The effect on the market is a structural procedural shift that expands total fusion biopsy volume independently of underlying prostate cancer incidence growth as the transperineal route progressively displaces transrectal biopsy at institutions that adopt the infection-control superiority evidence base. These are some of the key factors driving revenue growth of the market.

However, the fusion biopsy market faces adoption constraints from the high capital cost of MRI-US fusion biopsy system installations ranging from USD 80,000 to USD 250,000 per platform, the upstream pre-biopsy MRI cost adding USD 600 to USD 1,500 per patient, and the ongoing prostate MRI scanner availability constraint in lower-income markets. The platform capital cost constraint is the most significant adoption barrier limiting community urology practice deployment below the addressable clinical demand ceiling, since USD 80,000 to USD 250,000 per system requires payback period evaluation against per-biopsy procedure revenue and case volume at each individual urology practice, and community urology practices with prostate biopsy volumes below 50 to 100 cases per year cannot generate payback within 3 to 5 years at current reimbursement rates without supplementary procedure volume from affiliated hospital programme referrals. Pre-biopsy multiparametric MRI adding USD 600 to USD 1,500 per patient is a second constraint, since the combined total cost of the MRI prerequisite and the fusion biopsy procedure itself creates a prostate cancer diagnostic workup cost per patient that exceeds the diagnostic budget caps in many middle-income country health systems and in US settings where high-deductible insurance plans expose patients to significant out-of-pocket imaging costs that reduce compliance with pre-biopsy MRI recommendations. MRI scanner availability per capita is a third constraint that the KOELIS-DeepHealth AI interpretation tool addresses only partially, since AI software cannot substitute for the physical absence of 1.5T or 3T MRI scanner infrastructure at secondary hospitals and community urology practices in low-resource settings, and in markets where the MRI availability bottleneck rather than the radiologist interpretation capacity is the primary constraint, software solutions do not accelerate fusion biopsy adoption. These factors substantially limit fusion biopsy market growth over the forecast period.

Based on product, the global fusion biopsy market is segmented into MRI-ultrasound fusion biopsy systems and accessories. MRI-US fusion biopsy systems hold the largest revenue share at approximately 85% of 2025 market revenue through hardware platform and software licence revenue, because the fusion biopsy system represents the primary capital investment in the procedure workflow and generates software subscription and maintenance revenue over its installed life alongside the initial hardware placement revenue. Philips UroNav holds the dominant US academic centre installed base position through the Invivo Corporation distribution network, and KOELIS Trinity holds the leading European position with 3D elastic registration technology differentiation. Accessories including fusion biopsy needles, registration probes, and training simulation is expected to register a rapid revenue growth rate in the global fusion biopsy market over the forecast period, driven by volume growth from transperineal biopsy adoption requiring specific transperineal needle and probe accessories above the consumable base for transrectal fusion biopsy.

Prostate cancer diagnosis application is expected to account for the largest revenue share in the global fusion biopsy market during the forecast period

Based on application, the global fusion biopsy market is segmented into prostate cancer diagnosis, active surveillance monitoring, and repeat biopsy after prior negative results. Prostate cancer diagnosis holds the largest revenue share, reflecting the dominant share of initial diagnostic biopsy procedures in total fusion biopsy procedure volume at urology programmes globally, driven by PSA-elevated patient referral volumes and the EAU 2024 guideline mandating pre-biopsy MRI plus targeted biopsy for biopsy-naive men with elevated PSA. Active surveillance monitoring is expected to register the fastest revenue growth rate in the global fusion biopsy market over the forecast period, driven by growing active surveillance programme patient populations at major academic urology centres managing low-risk prostate cancer without immediate treatment, with Philips UroNav and KOELIS Trinity systems both supporting serial targeted biopsy monitoring for active surveillance patients that generates repeat procedure volume from the same patient over multi-year monitoring periods.

Based on biopsy route, the global fusion biopsy market is segmented into transrectal and transperineal approaches. Transrectal currently holds the largest revenue share as the established approach used at the majority of MRI-US fusion biopsy installations globally. Transperineal fusion biopsy is expected to register the fastest revenue growth rate in the global fusion biopsy market over the forecast period, driven by the infection-control superiority argument eliminating the approximately 1 to 3 percent post-TRUS sepsis rate, the KOELIS Trinity March 2025 US launch enabling both routes from the same platform, and Perineologic and BiopSee grid-based transperineal systems enabling office-based transperineal biopsy without general anaesthesia. BK Medical's January 2025 AI-guided transperineal navigation upgrade confirms the competitive investment in the transperineal segment across multiple platform vendors.

Based on regional analysis, the fusion biopsy market in North America accounted for largest revenue share in 2025. The United States leads because Philips UroNav through the Invivo Corporation subsidiary holds the dominant installed base at US academic and community urology centres, CMS reimbursement under CPT 76940 provides established coverage for MRI-guided prostate biopsy, and KOELIS Trinity's March 2025 US commercial launch expanded competitive platform availability for transrectal and transperineal fusion biopsy in outpatient urology settings. The 2018 USPSTF recommendation to discuss PSA screening with men aged 55 to 69 drove a partial recovery in US PSA screening rates following the 2012 USPSTF recommendation against PSA screening, benefiting fusion biopsy volume by increasing the total patient population referred for prostate biopsy evaluation.

The market in Europe is expected to register the fastest CAGR among established markets. Germany, the United Kingdom, and France represent the three largest national fusion biopsy device markets within Europe, with EAU 2024 guideline mandating pre-biopsy MRI plus targeted biopsy creating institutional compliance procurement at European hospital urology programmes that previously used conventional TRUS systematic biopsy. KOELIS has been the primary European beneficiary in France and francophone Europe through home market advantage and Trinity 3D elastic registration clinical differentiation, while Philips UroNav remains dominant at German university urology centres. The KOELIS-DeepHealth September 2024 AI integration is commercially significant for Southern and Eastern European hospitals where specialist prostate MRI radiologist capacity is the primary fusion biopsy adoption barrier.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, South Korea, China, and Australia represent the four largest national fusion biopsy markets within Asia Pacific, with Japan's PMDA regulatory pathway providing streamlined market access for Philips UroNav and KOELIS Trinity systems following FDA or CE approval. The prostate cancer incidence trajectory in Asia Pacific, with GLOBOCAN 2022 documenting meaningful incidence growth in Japan and South Korea driven by PSA screening adoption and the dietary-lifestyle westernisation associated with prostate cancer risk factor accumulation, leaves more room for fusion biopsy adoption growth than in North America or Western Europe where academic centre penetration is already advanced.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national fusion biopsy markets within the region, concentrated at private hospital urology programmes and academic urology centres in Sao Paulo, Mexico City, and Bogota. Iran-US sanctions and Strait of Hormuz freight disruption through 2026 have maintained elevated import costs for fusion biopsy platform components and MRI scanner infrastructure entering Brazilian and Mexican medical device distribution networks, moderating the pace of platform deployment at secondary hospital urology programmes.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, Israel, the UAE, and South Africa represent the primary commercial fusion biopsy markets within the region, with King Faisal Specialist Hospital and Research Centre in Riyadh and Sheba Medical Centre in Israel representing the leading academic urology programme deployment sites for Philips UroNav and KOELIS Trinity platforms.